"Inactivating" PF4: a new approach to HIT treatment?
Current methods of treating heparin-induced thrombocytopenia (HIT) focus on treatment and prevention of thrombotic complications. In this issue of Blood, Sachais et al describe a novel therapeutic approach: pharmacologic disruption of PF4 tetramers essential for formation of immune complexes that are central to the pathogenesis.
BloodCenter of Wisconsin.
Richard H
RH
Aster